Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysisBMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e7437 (Published 02 November 2012) Cite this as: BMJ 2012;345:e7437
Changes made at the proof stage to this Research paper by Mark Rozenbaum and colleagues resulted in an error in the abstract (BMJ 2012;345:e6879, doi:10.1136/bmj.e6879). The third sentence of the results section stated the opposite meaning of what it was meant to convey. This sentence should have concluded that if the vaccine does [not “if the vaccine does not”] offer protection against non-bacteraemic pneumococcal pneumonia or the vaccine was introduced concomitantly with the infant 13 valent pneumococcal conjugate vaccination programme then vaccinating high risk people would (more) likely be cost effective.
Cite this as: BMJ 2012;345:e7437